Rapalogix Health Raises $20M in Series A Funding Round

The company plans to use the funding to expand commercial activities for Re-Q, support clinical and translational research, develop new products focused on skin longevity, hair health, and other age-related skin conditions, and strengthen its scientific, medical, and commercial teams.

The funding comes after a period of strong growth and recognition for Rapalogix Health. In 2026, the company received several industry awards, expanded its leadership team, and grew its commercial salesforce to support the nationwide launch of Re-Q.

Read More:Solar Landscape Closes $125M Debt Funding Led by M&T Bank

As part of this funding round, Rapalogix also appointed Neetu Dhaliwal, and Dr. Craig Gordon to its Board of Directors, further strengthening the companys leadership and governance as it enters its next stage of growth.

Rapalogix's lead product, the Pro-Longevity Face Serum from its Re-Q skincare line, is built on the company's proprietary technology that selectively modulates TORC1 activity in skin cells. This approach is based on Cambrian Bio's TORnado platform, which solved a long-standing challenge in achieving selective TORC1 modulation. Rapalogix was created to apply this breakthrough to skin health and longevity.

By supporting important cellular processes linked to skin function and resilience, the company aims to introduce a new approach to healthy skin aging and long-term skin wellness.

"This financing marks a significant milestone for Rapalogix and reflects the strength of the science underlying our platform," said Dr. Mehta, CEO of Rapalogix Health. "We're building toward a future where skin health and longevity are addressed at the cellular level, and this capital enables us to bring that vision to more patients and physicians across the country while advancing our next generation of therapeutics. Our growth strategy puts our premier dermatology physician partners at the forefront, as we collaborate directly with them to drive clinical innovation and advance longevity science in dermatology."

"For years, dermatology has largely focused on treating the visible manifestations of aging," commented Dr. Day. "What excites me about Rapalogix is its focus on the biology that drives skin aging. Advances in longevity science are creating opportunities to rethink how we support skin health and we believe we are only beginning to unlock that potential."

"We're still in the early innings of understanding how longevity science can transform human health. Our vision is to build the leading longevity-based skin health company and create products grounded in rigorous science that help people maintain healthier skin as they age," commented Saunders.

About Rapalogix Health

Founded in 2024 by Rahul Mehta, Rapalogix Health is a California based biotechnology company focused on advancing skin health through longevity science. The company uses scientific research to develop innovative dermatology treatments and professional skincare products. Rapalogix is building a pipeline of prescription therapies, and skincare solutions designed to support healthier aging. Its first product, Re-Q Pro-Longevity Face Serum, is available through dermatology and aesthetic practices across the United States.

Read More:Allium Raises $40M in Series B Funding Led by Amplify Partners